HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env Glycan-specific lectin devoid of T-cell mitogenic activity

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Matoba, Nobuyuki ^a,b   Husk, Adam S ^a   Barnett, Brian W ^a   Pickel, Michelle M ^c   Arntzen, Charles J ^c   Montefiori, David C ^d   Takahashi, Atsushi ^e   Tanno, Kazunobu ^f   Omura, Satoshi ^g   Cao, Huyen ^h   Mooney, Jason P ^h   Hanson, Carl V ^h   Tanaka, Haruo ^e,f  

^a Owensboro Cancer Research Program   (United States)

^b University of Louisville School of Medicine   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e IWAKI MEISEI UNIVERSITY   (Japan)

^f KIIM Pharmaceutical Laboratories Inc   (Japan)

^g KITASATO UNIVERSITY   (Japan)

^h CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINOHIVIN; LECTIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MITOGENICITY; NICOTIANA BENTHAMIANA; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLANT BIOTECHNOLOGY; SYNCYTIUM; T LYMPHOCYTE; TOBACCO MOSAIC VIRUS; VIRUS NEUTRALIZATION;

BACTERIAL PROTEINS; CELL PROLIFERATION; HELA CELLS; HIV-1; HUMANS; MITOGENS; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TOBACCO;

HUMAN IMMUNODEFICIENCY VIRUS 1; NICOTIANA BENTHAMIANA; TOBACCO MOSAIC VIRUS;

EID: 77956210451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011143     Document Type: Article

References (58)

1. AIDS epidemic update (2009) AIDS epidemic update: Joint United Nations Programme on HIV/AIDS & World Health Organization.
2. Garg AB, Nuttall J, Romano J (2009) The future of HIV microbicides: challenges and opportunities. Antivir Chem Chemother 19: 143-150.
3. McGowan I (2010) Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 23: 26-31.
4. Morris GC, Lacey CJ (2010) Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 23: 57-63.
5. Grant RM, Hamer D, Hope T, Johnston R, Lange J, et al. (2008) Whither or wither microbicides? Science 321: 532-534.
6. Scanlan CN, Offer J, Zitzmann N, Dwek RA (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038-1045.
7. Balzarini J (2007) Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 5: 583-597.
8. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM (2010) A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem.
9. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, et al. (2005) Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 102: 13372-13377.
10. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
11. Chiba H, Inokoshi J, Okamoto M, Asanuma S, Matsuzaki K, et al. (2001) Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities. Biochem Biophys Res Commun 282: 595-601.
12. Tanaka H, Chiba H, Inokoshi J, Kuno A, Sugai T, et al. (2009) Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 106: 15633-15638.
13. Takahashi A, Inokoshi J, Chiba H, Omura S, Tanaka H (2005) Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete. Arch Biochem Biophys 437: 233-240.
14. Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, et al. (2003) Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 77: 1337-1346.
15. Chiba H, Inokoshi J, Nakashima H, Omura S, Tanaka H (2004) Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. Biochem Biophys Res Commun 316: 203-210.
16. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, et al. (2009) International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 4: e4505.
17. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, et al. (1995) Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9: 867-874.
18. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, et al. (1996) Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses 12: 1319-1328.
19. Wang CY, Sawyer LS, Murthy KK, Fang X, Walfield AM, et al. (1999) Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci U S A 96: 10367-10372.
20. Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, et al. (2004) Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol 173: 2184-2189.
21. Fraser JD, Proft T (2008) The bacterial superantigen and superantigen-like proteins. Immunol Rev 225: 226-243.
22. Montefiori DC (2009) Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 485: 395-405.
23. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14: 1229-1246.
24. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, et al. (2004) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci U S A 101: 6852-6857.
25. Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol 23: 718-723.
26. Chiba H, Asanuma S, Okamoto M, Inokoshi J, Tanaka H, et al. (2001) A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines-establishment and validation. J Antibiot (Tokyo) 54: 818-826.
27. Sharon N, Lis H (2004) History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 14: 53R-62R.
28. Gavrovic-Jankulovic M, Poulsen K, Brckalo T, Bobic S, Lindner B, et al. (2008) A novel recombinantly produced banana lectin isoform is a valuable tool for glycoproteomics and a potent modulator of the proliferation response in CD3+, CD4+, and CD8+ populations of human PBMCs. Int J Biochem Cell Biol 40: 929-941.
29. Huskens D, Vermeire K, Vandemeulebroucke E, Balzarini J, Schols D (2008) Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 40: 2802-2814.
30. Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80: 8411-8421.
31. Lederman MM, Jump R, Pilch-Cooper HA, Root M, Sieg SF (2008) Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology 5: 116.
32. Pope M, Haase AT (2003) Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9: 847-852.
33. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 358: 1590-1602.
34. Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81: 10209-10219.
35. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.
36. Inokoshi J, Chiba H, Asanuma S, Takahashi A, Omura S, et al. (2001) Molecular cloning of actinohivin, a novel anti-HIV protein from an actinomycete, and its expression in Escherichia coli. Biochem Biophys Res Commun 281: 1261-1265.
37. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315-320.
38. Keller MJ, Herold BC (2009) Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm Dis 36: S92-95.
39. Willey RL, Shibata R, Freed EO, Cho MW, Martin MA (1996) Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J Virol 70: 6431-6436.
40. Liedtke S, Geyer R, Geyer H (1997) Host-cell-specific glycosylation of HIV-2 envelope glycoprotein. Glycoconj J 14: 785-793.
41. Yuste E, Reeves JD, Doms RW, Desrosiers RC (2004) Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol 78: 6775-6785.
42. Bachrach E, Dreja H, Lin YL, Mettling C, Pinet V, et al. (2005) Effects of virion surface gp120 density on infection by HIV-1 and viral production by infected cells. Virology 332: 418-429.
43. Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, et al. (2006) Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J Virol 80: 6324-6332.
44. Paranjpe S, Craigo J, Patterson B, Ding M, Barroso P, et al. (2002) Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum Retroviruses 18: 1271-1280.
45. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, et al. (2009) Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A.
46. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194-11204.
47. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
48. Cutalo JM, Deterding LJ, Tomer KB (2004) Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom 15: 1545-1555.
49. Shenoy SR, Barrientos LG, Ratner DM, O'Keefe BR, Seeberger PH, et al. (2002) Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. Chem Biol 9: 1109-1118.
50. Botos I, O'Keefe BR, Shenoy SR, Cartner LK, Ratner DM, et al. (2002) Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem 277: 34336-34342.
51. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, et al. (2003) Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 19: 535-541.
52. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20: 11-18.
53. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, et al. (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90: 234-243.
54. Zeitlin L, Pauly M, Whaley KJ (2009) Second-generation HIV microbicides: continued development of griffithsin. Proc Natl Acad Sci U S A 106: 6029-6030.
55. Ma JK, Chikwamba R, Sparrow P, Fischer R, Mahoney R, et al. (2005) Plant-derived pharmaceuticals-the road forward. Trends Plant Sci 10: 580-585.
56. Matoba N, Davis KR, Palmer KE (in press) Recombinant Protein Expression in Nicotiana. Methods Mol Biol. (in press).
57. Matoba N, Kajiura H, Cherni I, Doran JD, Bomsel M, et al. (2009) Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR(649-684). Plant Biotechnol J 7: 129-145.
58. Alouf JE, Muller-Alouf H (2003) Staphylococcal and streptococcal superantigens: molecular, biological and clinical aspects. Int J Med Microbiol 292: 429-440.